Third-Party Oversight Of Device Changes Urged In Formal Complaint
This article was originally published in The Gray Sheet
Executive Summary
FDA should amend its policy on device modifications to require their review by an independent third party, or the agency itself, prior to marketing, according to a Jan. 14 formal complaint
You may also be interested in...
Boston Scientific Pursues Dual Strategy In Addressing RotaLink Recall
Boston Scientific may opt to restart production of its original Rotablator atherectomy system following the Aug. 6 recall of the next-generation RotaLink Plus, the company reported at a same-day teleconference.
Biden Extends Helping Hand To Small US Manufacturers, Vendors With ‘Made In America’ EO
The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.
Warning Letter Roundup & Recap – 26 January 2021
No device-related warning letters were released by the US FDA the week of 26 January.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: